NantKwest (NK) IPO Opens Up 48%

NantKwest Inc. (Nasdaq: NK) to Ring The Nasdaq Stock Market Closing Bell

ADVISORY, July 28, 2015 (GLOBE NEWSWIRE) --

What:  NantKwest (Nasdaq: NK), is a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases. NK cells are the bodys first line of defense due to the innate ability of NK cells to rapidly identify and destroy cells under stress, such as cancer or virally-infected cells.

NantKwests unique NK cell based platform, with the capacity to grow active killer cells... More

NantKwest Inc. (Nasdaq: NK) to Ring The Nasdaq Stock Market Closing Bell

ADVISORY, July 28, 2015 (GLOBE NEWSWIRE) --

What:  NantKwest (Nasdaq: NK), is a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases. NK cells are the bodys first line of defense due to the innate ability of NK cells to rapidly identify and destroy cells under stress, such as cancer or virally-infected cells.

NantKwests unique NK cell based platform, with the capacity to grow active killer cells... More

NantKwest Announces Pricing of Initial Public Offering

CULVER CITY, Calif.--(BUSINESS WIRE)-- NantKwest, Inc. (formerly Conkwest, Inc.), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases, announced today the pricing of its initial public offering of 8,288,000 shares of its common stock at a price to the public of $25.00 per share. All of the shares are being offered by NantKwest. The shares are expected to begin trading on The Nasdaq Global Select Market on July 28, 2015, under the symbol "NK." In addition, NantKwest has granted the underwriters... More